Ceryvyn Outlines LAM Drug Development Focus as Shares Fall 9%
CYV: $0.010 -9.09% · MC: $12M
Ceryvyn Therapeutics’ November investor presentation highlights CYV-101, an investigational fusion protein it intends to test in lymphangioleiomyomatosis, a rare lung disease; the excerpt provides no new clinical or financial guidance. Shares fell around 9% on the day, alongside the presentation.

Comments